Based on the glutamate–urea–lysine (GUL) structure, Lu-177 Ludotadipep is designed to extend the circulation time by binding to albumin, reducing non-specific organ uptake, increasing total tumor absorption, and lowering the side effects with smaller doses (Figure 4) [71,93,94]. The gene discussed is ALB; the disease is neoplasm.